Himira’s biosimilar successfully passes clinical trials
AbbVie’s Humira is the world’s top-selling drug with this year’s second quarter revenue of $3.29 bln according to IMS Health. The products will lose patent protection in 2016.
Humira’s generic developed by Amgen is demonstrating equivalent to the original preparation efficacy in late-stage clinical trials. American company Amgen is currently developing 6 biosimilars and is planning to begin their marketing in 2017.
Source: Drug Discovery & Development